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Abstract
The stability and bioavailability of anticancer agents, such as gemcitabine, can be increased by forming prodrugs. Gemcitabine is rapidly
deaminated to the inactive metabolite (2′,2′-difluorodeoxyuridine), thus to improve its stability a series of increasingly lipophilic gemcitabine
prodrugs linked through the 4-amino group to valeroyl, lauroyl, and stearoyl acyl chains were synthesized. Studies of monolayer properties
are important to improve understanding of biological phenomena involving lipid/gemcitabine or lipid/gemcitabine derivative interactions. The
interfacial behavior of monolayers constituted by DMPC plus gemcitabine or lipophilic gemcitabine prodrugs at increasing molar fractions was
studied at the air/water interface at temperatures below (10 ◦C) and above (37 ◦C) the lipid phase transition. The effect of the hydrophobic chain
length of gemcitabine derivatives on the isotherm of pure DMPC was investigated by surface tension measurement, and the results are reported as
molar fractions as a function of mean molecular area per molecule. The results show that the compounds interact with DMPC producing mixed
monolayers that are subject to an expansion effect, depending on the prodrug chain length. The results give useful hints of the interaction of these
prodrugs with biological membranes and increase knowledge on the incorporation site of such compounds, as a function of their lipophilicity, in
a lipid carrier; they may lead to improved liposomal formulation design.
© 2007 Elsevier Inc. All rights reserved.
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Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), a pyrimidine
antimetabolite [1], is known to be active against a variety of
solid tumors, and is well tolerated in clinical trials [2–4].
One disadvantage of gemcitabine is its rapid and extensive
deamination to its inactive metabolite 2′,2′-difluorodeoxyuri-
dine by cytidine deaminase in the blood, liver, kidney and
other tissues [5] and its subsequent excretion in the urine; the
plasma half-life is very short (8–17 min). An approach to im-
prove gemcitabine’s metabolic stability and the related cyto-
toxic activity is to protect the amide group by forming pro-
drugs and/or by incorporating the prodrugs into lipid vesicles.
* Corresponding author. Fax: +39 095 580138.
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doi:10.1016/j.jcis.2007.04.018In order to understand the therapeutic action of any drug it is
very important to know its interaction with the biomembrane
lipids.
Differential scanning calorimetry (DSC) has recently been
employed to study the interaction of gemcitabine and three of
its acylic prodrugs, 4-(N )-valeroyl-gemcitabine (Gem-C5), 4-
(N )-lauroyl-gemcitabine (Gem-C12) and 4-(N )-stearoyl-gem-
citabine (Gem-C18) (Scheme 1) with biomembrane models
(phospholipid multilamellar vesicles) in order to evaluate the
effect of acyl chain length on the prodrugs/lipid interaction
[6]. This study used dimyristoylphosphatidylcholine (DMPC)
monolayers as biomembrane model and the Langmuir–Blodgett
(LB) technique to obtain additional information over that of-
fered by the calorimetric technique.
The Langmuir–Blodgett technique, which uses phospho-
lipid monolayers, is one of the commonest ways to study
the interaction between drugs and phospholipids. Monolay-
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ers are an excellent model to study two-dimensional ordering,
with two thermodynamical variables, temperature and pressure,
being readily controlled [7–9]. The physico-chemical analy-
sis of the LB results may provide important information on
the organization of biological compounds in the lipid mem-
brane.
The film-balance method enables phase diagrams of phos-
pholipids to be obtained; these are generally in the form of
surface pressure/mean molecular area (π/Å2) isotherm curves.
The phospholipids are spread over an aqueous subphase, pro-
viding monomolecular distribution and the subsequent varia-
tion of the available area per molecule. If the monolayer is
submitted to compression, the molecules’ surface distribution
changes and they are forced to go from a “gaseous” or “liq-
uid expanded” (LE) phase at low density to a “liquid con-
densed” (LC) phase at a higher density and, successively, to
a “solid condensed” phase [10]. In multicomponent monolay-
ers spread over a liquid, the two dimensional miscibility of
the components is a significant problem. Conclusions about the
mixing process of two pure monolayers can be made by com-
paring surface pressure-area isotherms of mixed and pure films.
Results provide indications on the compounds’ ability to dis-
solve in the phospholipid molecules used as model membrane.
The interactions enable hypothesis to be made about the in-
take and collocation of the compounds within the membrane
[11–13].
The Langmuir–Blodgett technique has been applied to
studying the interaction of phospholipid membranes with an-
titumor drugs including doxorubicin and paclitaxel. Paclitaxel
has been found to be miscible in the lipid monolayer and
a repulsive interaction between paclitaxel and the lipid was
concluded to exist. It has been recognized that differences in
phospholipid molecular structure, such as lipid chain length,
chain unsaturation and head group type, as well as the presence
of cholesterol, may profoundly affect drug–membrane inter-
actions; paclitaxel affects membrane morphology and stability
more easily when phospholipids with shorter chains are present
[14–19].2. Experimental
2.1. Materials
Gemcitabine was synthesized in our laboratory as described
in [20]. The 4-(N )-acyl-gemcitabine derivatives were synthe-
sized and characterized as reported elsewhere [21].
1,2-Dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC)
was supplied by Genzyme Pharmaceuticals (Liestal, Switzer-
land). All reagents and solvents used were of analytical grade.
2.2. Langmuir film balance
A film balance apparatus, KSV Langmuir minitrough (KSV,
Instruments Ltd., Finland), was used. It includes a trough
(24,225 mm2 available area for the monolayer formation)
coated with polytetrafluoroethylene (Teflon) and surrounded
by a water jacket providing temperature control, and two
mechanically-coupled barriers of hydrophilic Delrin. The film
pressure at the air/water interface was measured using the Wil-
helmy plate arrangement attached to a microbalance. A plat-
inum plate was suspended for film pressure measurements.
5 mM phosphate buffer (pH 7.4) in ultrapure Millipore wa-
ter with resistance of 18.2 M was used as subphase. Surface
purity of monolayers was checked by closing and opening the
barriers and ensuring that surface pressure readings did not dif-
fer by more than ±0.1 mN/m. The KSV system was checked
using stearic acid [22].
2.3. Mixed monolayer surface pressure/molecular area
isotherms
DMPC, gemcitabine and 4-(N )-acyl-gemcitabine conju-
gates were prepared at equimolar concentrations in chloro-
form (Aldrich, 99.9%). Appropriate volumes of DMPC and
gemcitabine or 4-(N )-acyl-gemcitabine derivatives were then
mixed to form DMPC/gemcitabine and DMPC/4-(N )-acyl-
gemcitabine derivatives at 0.015, 0.03, 0.045, 0.06, 0.09, 0.12,
0.25, 0.50, and 0.75 molar fractions. Aliquots of about 30 µl
of the above mixtures, as well as of solutions of the pure
components were spread drop by drop onto the aqueous sub-
phase using a Hamilton syringe. After waiting 15 min for
solvent evaporation, the films were linearly compressed with
the two mobile barriers at a rate of 10 (mN/m)/min and the
surface pressure vs molecular area isotherms were recorded.
The experiments were performed at subphase temperatures of
10 and 37 ◦C, (temperatures below and above the phase tran-
sition temperature of DMPC), to allow considerations both at
physiological temperature (37 ◦C) at which DMPC is in a dis-
ordered state, and at a temperature (10 ◦C) at which the DMPC
is in an ordered state. The effect of a foreign compound dis-
solved in the ordered lipid structure can then be amplified
giving more information on its packing in the lipid matrix
and on the consequent loss of lipid cooperativity. Each exper-
iment was repeated at least three times to obtain reproducible
results.
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DMPC, gemcitabine, and 4-(N )-acyl-gemcitabine conjugates at the air/water
interface at (A) 10 ◦C and (B) 37 ◦C.
3. Results and discussion
3.1. DMPC, gemcitabine and gemcitabine derivatives
monolayers
The compression surface pressure-area per molecule (mN/
m-Å2) isotherms of pure compounds are plotted in Fig. 1. We
will analyze the isotherms recorded at 10 ◦C first (Fig. 1A). The
DMPC isotherm shows characteristic features: a gaseous phase
for areas larger than 100 Å2, a LE phase at 100 < Å2 < 70,
a LE to LC lipid phase transition between 70 and 45 Å2 and
a LC phase for areas lower than 45 Å2 [23,24]. Gemcitabine
does not form a monolayer and even at high concentrations no
isotherm is observable. No isotherms are visible for Gem-C5.
This compound, probably because of its hydrophilic character,
either does not form monolayers or remains in a gaseous state
even at high compression. Gem-C12 exists in a gaseous phase
for areas larger than 50 Å2, whereas for areas lower than 50 Å2
it exists in a LC phase. Gem-C18 isotherms indicate that the
compound is in a LC phase for areas lower than 35 Å2, whereas
in larger areas it is in a gaseous phase. With regard to the re-
sults obtained at 37 ◦C (Fig. 1B), the DMPC isotherm curve is
shifted toward higher area per molecule values than at 10 ◦C.
In addition it also shows a gaseous (130–110 Å2) and a LE
(below 110 Å2) state with no evidence of the LE/LC transi-
tion. Gem-C5, likewise is unable to form a monolayer at 37 ◦C.
Gem-C12 exists in a gaseous state in areas larger than 45 Å2, ina LE state between 20 and 45 Å2, and in a LC state for lower
areas. The behavior of Gem-C18 at 37 ◦C is similar to that ob-
served at 10 ◦C but the LE/LC transition occurs between 45 and
35 Å2. The isotherm of Gem-C18 is steeper than that of Gem-
C12, which may depend on the tilt angle of the prodrug at the
air water interface. The longer the acyl chain of the prodrug,
the more hydrophobic it becomes and the less likely it is to be
in the liquid expanded state with the chains tilted at the inter-
face [25].
3.2. Mixed monolayers of DMPC and gemcitabine or
gemcitabine derivatives
Mixtures of DMPC and each of the studied compounds,
prepared at compounds molar fractions ranging from 0.015 to
0.75, were spread at the air/water interface and their isotherms
recorded. We compared the isotherms of the DMPC/Gem and
DMPC/Gem-derivative mixtures with that of pure DMPC and
evaluate the change produced in the pure DMPC isotherm by
the compound (data not shown).
Gemcitabine: at 10 ◦C and 0.015 molar fraction it causes a
shift toward higher molecular areas, while higher molar frac-
tions shift the isotherm toward lower areas. In addition, the
DMPC LE/LC phase transition is also shifted toward higher
value of surface pressure, and becomes less marked. At 37 ◦C,
at low molar fraction (0.015 and 0.03) of gemcitabine the
isotherms are shifted toward larger areas, whereas at higher mo-
lar fractions of gemcitabine the isotherms are shifted toward
lower areas.
Gem-C5: at 10 ◦C, 0.015 and 0.03 Gem-C5 molar fractions
cause the isotherms to shift toward larger molecular areas,
whereas higher molar fractions cause the isotherm to move to-
ward lower molecular area. This does not occur at 37 ◦C where
the isotherm is shifted toward lower areas as the Gem-C5 con-
centration increases.
Gem-C12: at 10 ◦C, isotherm shape and molecular area are
almost unchanged at molar fractions of Gem-C12 ranging from
0.015 to 0.12; higher molar fractions cause the isotherm shift
toward lower area together with a gradual disappearance of the
LE/LC phase transition which is shifted toward higher value of
surface pressure. At 37 ◦C, similarly to what occurs at 10 ◦C,
low Gem-C12 molar fractions do not cause substantial change
of the isotherm, whereas high molar fractions (0.5, 0.75) cause
the isotherm to shift toward lower molecular area.
Gem-C18: the behavior of the DMPC isotherm in the pres-
ence of Gem-C18, at 10 ◦C, is very similar to that occurring
with Gem-C12: there is no significant change with 0.015–0.12
molar fractions and a shift toward lower molecular areas at
higher molar fractions. As the Gem-C18 molar fraction in-
creases, the LE/LC phase transition gradually shifts toward
higher values of surface pressure, at the same time becoming
less evident; it disappears entirely at 0.75 molar fraction and
isotherm shows only a liquid condensed phase region. At 37 ◦C,
all the DMPC/Gem-C18 mixture isotherms are shifted toward
lower molecular areas. In the isotherm at 0.75 molar fraction a
LE/LC transition occurs between 55 and 45 Å2.
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tion of compounds mixed with phospholipids have been re-
ported, giving information on molecular distribution, miscibil-
ity and interaction among molecules contained in mixed mono-
layers [26]. The mean molecular area of a two components
monolayer is calculated as A = A1X1 +(1−X1)A2; where A is
the mean molecular area, X1 is the molar fraction of a compo-
nent, and A1 and A2 are the areas of the two pure components
at the same surface pressure. Graphs of A as a function of X1
are linear if either the components are completely immiscible
or they possess an ideal miscibility [22]. Any deviation from
the straight line indicates an interaction between the molecules.
Fig. 2 shows the area per molecule as a function of the gem-
citabine or gemcitabine-prodrug molar fraction at 10 ◦C and at
pressure of 10 (before the LE/LC transition), 20 (just after the
LE/LC transition) and 35 mN/m (at high compression); exper-
imental values are shown in solid lines and ideal ones in dotted
lines.
Gemcitabine: Fig. 2A shows the area per molecule as a func-
tion of the gemcitabine molar fraction in the DMPC/gemcitab-
ine mixtures at 10 ◦C. With respect to the ideal line, at 10 and
20 mN/m, small molar fractions give a small positive deviation,
whereas for high molar fractions experimental values coincide
with ideal values. At 35 mN/m, experimental values coincide
with ideal values up to 0.25 molar fraction, after which negative
deviations occur. This shows a repulsive interaction between the
molecules which disappears at the highest pressure value em-
ployed due to the high compression. At 37 ◦C, and pressures of
10 and 20 mN/m, there is generally a positive deviation which
becomes less marked at high molar fractions; at 35 mN/m, as
the molar fraction increases, positive deviation still occurs, fol-
lowed by coincidence with the ideal line and lastly a negative
deviation above 0.75 (Fig. 2B).
Gem-C5: at 10 ◦C (Fig. 2C), at all surface pressures tested,
there is a slight positive deviation from the ideal line at low
(0.015–0.06) and high molar fractions (0.5 and 0.75), whereas
at intermediate molar fractions the experimental values coin-
cide with the ideal values. At 37 ◦C (Fig. 2D), a negative de-
viation occurs for molar fractions between 0.015 and 0.25 and
a positive deviation at the 0.5 molar fraction; the 0.75 molar
fraction induces a positive deviation at 10 and 20 mN/m and
a negative deviation at 35 mN/m. These results indicate that
Gem-C5, at 10 ◦C, exerts a small expansion effect on DMPC
meaning that there are repulsive forces between the molecules.
At 37 ◦C, the negative and positive deviations that occur, re-
spectively, at low and high Gem-C5 molar fractions, indicate,
respectively, attractive and repulsive forces. This effect could
be explained by assuming that: (1) Gem-C5, due to its par-
tially hydrophilic character, localizes parallel to the subphase
surface, causing the DMPC molecules to move away; this lo-
calization is favored by low temperatures, when DMPC is in an
ordered state; (2) Gem-C5’s hydrophobic tail is parallel to the
DMPC hydrophobic chains; however, its length being shorter
than that of the DMPC chains, the interaction among phospho-
lipid chains decreases.
Gem-C12: the behavior of DMPC/Gem-C12 mixtures is
quite different. At 10 ◦C (Fig. 2E), a positive deviation occursat 10 mN/m for all molar fractions, apart from 0.75, which pro-
duces a negative deviation. At 20 mN/m, the deviation is neg-
ative, positive and then again negative on passing from lower
to higher molar fraction. At 35 mN/m and molar fractions be-
tween 0.015 and 0.12, experimental values coincide with ideal
values, whereas at higher molar fractions the deviation is neg-
ative. At 37 ◦C (Fig. 2F) and at 10 and 20 mN/m, there is a
positive deviation for all molar fractions; at 35 mN/m, small
negative and positive deviations alternate. At both temperatures
and at 10 and 20 mN/m, Gem-C12 exerts an expanding effect
which is more pronounced at 37 ◦C. At 35 mN/m, the mole-
cules occupy a lower area than the ideal one, probably because
the stronger compression makes the attractive forces dominate.
Gem-C18: at 10 ◦C (Fig. 2G), a positive deviation is seen
at 10 and 20 mN/m, the deviation being more pronounced at
20 mN/m. At a surface pressure of 35 mN/m, and at low pro-
drug molar fractions, there is a very slight positive deviation,
whereas at high molar fractions experimental values coincide
with ideal values. At 37 ◦C (Fig. 2H), 10 mN/m and low mo-
lar fractions of Gem-C18, a small negative deviation occurs,
while at high molar fractions the deviation becomes positive.
At 20 mN/m experimental values coincide with the ideal ones
and at 35 mN/m, there is a small negative deviation.
The relationship between actual molecular occupied area
and molar fraction of the compounds studied is not linear, thus
the compounds and DMPC were postulated to be miscible,
and to show non-ideal mixed behavior in the monolayer at the
air/water interface.
We found that gemcitabine and Gem-C5 did not show any
isotherm, whereas Gem-C12 and Gem-C18, because of their
long hydrophobic tails, showed well-defined isotherms. Gem-
C12, with a shorter hydrophobic tail, is in a well-defined LC
phase only at 10 ◦C, whereas at 37 ◦C there is also a LE phase
because at this temperature the thermal motion overcomes the
hydrophobic forces. The Gem-C18 isotherm indicates there is
an LC state at 10 ◦C, whereas at 37 ◦C there is also a LE/LC
transition.
Comparing the results, it is apparent that gem-derivatives
in mixed monolayers substantially exert an expansion effect,
which is particularly strong in the case of Gem-C12. Gem-
C5, although it possesses a much shorter hydrophobic tail than
C-18, exerts a similar effect: Gem-C5, with a much shorter
chain than DMPC, enables the DMPC chains to interact with
each other. Gem-C18, possessing a longer chain than DMPC,
interacts with the phospholipid chains; the slight expansion ef-
fect might be due to the long chain tilting.
The more pronounced expanding effect on DMPC molecules
that is caused by Gem-C12, compared to that of Gem-C18 at
37 ◦C and at 10 and 20 mN/m, could be due to the fact that at
this temperature and surface pressure Gem-C12 is still in a LE
phase, occupying a larger area than Gem-C18.
Gem-C12, with its 12-carbon tail, gives a smaller contri-
bution to the hydrophobic forces than do DMPC chains, thus
permitting the molecule to occupy a larger area.
From our previous DSC study, we learned that gemcitabine
is unable to perturb (penetrate) a lipid multilayer (monolayer);
moreover, when bound to fatty acids, to form 4-(N )-acyl deriva-
F. Castelli et al. / Journal of Colloid and Interface Science 313 (2007) 363–368 367Fig. 2. Molecular area of the mixed monolayers of DMPC and gemcitabine or gemcitabine prodrug at the air/water interface plotted as a function of the molar
fraction of gemcitabine or its prodrug at various surface pressure. (A) DMPC/gemcitabine 10 ◦C; (B) DMPC/gemcitabine 37 ◦C; (C) DMPC/Gem-C5 10 ◦C;
(D) DMPC/Gem-C5 37 ◦C; (E) DMPC/Gem-C12 10 ◦C; (F) DMPC/Gem-C12 37 ◦C; (G) DMPC/Gem-C18 10 ◦C; (H) DMPC/Gem-C18 37 ◦C.tives prodrugs, it interacts more strongly with the biomembrane
models, the extent of interaction depending on the acyl chain
length of phospholipid and prodrug. The DSC results showedthat all prodrugs generally exerted a destabilizing effect on the
lipid bilayer [6]. The present data are in agreement with the
previously study [6] since the compounds substantially exert
368 F. Castelli et al. / Journal of Colloid and Interface Science 313 (2007) 363–368an expansion effect on the mixed monolayers. Conjugation of
gemcitabine with short, medium, and long-acyl side chain of-
fers a set of molecular tools that could be helpful to evaluate
the effects of the increasing lipophilicity on their interaction
with biological membranes. In addition, these findings may be
of use for optimizing liposomal formulations of gemcitabine
prodrugs for use in anticancer treatment.
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